

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
04 February 2021 (04.02.2021)



(10) International Publication Number  
**WO 2021/019471 A1**

(51) International Patent Classification:

C12N 15/867 (2006.01) C12N 15/113 (2010.01)  
A61K 35/17 (2015.01) C12N 15/12 (2006.01)  
A61P 35/00 (2006.01) C12N 15/63 (2006.01)  
C07K 14/725 (2006.01) C12N 5/0783 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/IB2020/057171

(22) International Filing Date:

29 July 2020 (29.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/880,505 30 July 2019 (30.07.2019) US

(71) Applicant: **UNIVERSITY HEALTH NETWORK**  
[CA/CA]; 101 College Street, Unit 150, Toronto, Ontario  
M5G-1L7 (CA).

(72) Inventors: **HIRANO, Naoto**; 101 College Street, Unit 150,  
Toronto, Ontario M5G-1L7 (CA). **SUGATA, Kenji**; 101  
College Street, Unit 150, Toronto, Ontario M5G-1L7 (CA).  
**SASO, Kayoko**; 101 College Street, Unit 150, Toronto, On-  
tario M5G-1L7 (CA).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(54) Title: T CELL RECEPTORS AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a MUC5AC epitope and nucleic acid molecules encoding the same. In some aspects, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some aspects, the methods comprise treating a cancer in a subject in need thereof.



WO 2021/019471 A1